The CHMP recommendation still needs European Commission sign-off. In trials, Foundayo users lost about 5% to 11% of body weight at 72 weeks depending on dose.
Recap by typeshit. Full story at Fierce Pharma.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
GoodRx keeps a running page on peptide regulation news, with a focus on what the FDA is doing about compounding pharmacies.
The European Commission typically rules about two months after the CHMP nod. In trials, the top dose of orforglipron cut around 11% of body weight over 72 weeks.
Loading…